dc.date.accessioned | 2024-01-12T18:01:31Z | |
dc.date.available | 2024-01-12T18:01:31Z | |
dc.date.created | 2024-01-02T10:23:51Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Holmberg, Marte Aass, Hans Christian Dalgard, Olav Samuelsen, Ellen Sun, Dan Björkström, Niklas K. Johannessen, Asgeir Reikvam, Dag Henrik . Treatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines. Scientific Reports. 2023, 13(1) | |
dc.identifier.uri | http://hdl.handle.net/10852/106765 | |
dc.description.abstract | Patients with HBeAg-negative chronic hepatitis B may experience an immune response after stopping nucleos(t)ide analogue (NA)therapy, which may potentially trigger HBsAg loss or off-therapy sustained viral control. The immunological mechanisms determining clinical response remain poorly understood. To identify inflammatory signatures associated with defined outcomes, we analysed plasma cytokines and chemokines from 57 HBeAg-negative patients enrolled in the Nuc-Stop Study at baseline and 12 weeks after NA cessation. Clinical response at 12 weeks was classified into four groups: immune control, viral relapse, evolving clinical relapse, and resolving clinical relapse. Twelve weeks after treatment cessation 17 patients (30%) experienced immune control, 19 (33%) viral relapse, 6 (11%) evolving clinical relapse, and 15 (26%) resolving clinical relapse. There was a significant increase in interferon-γ-induced protein 10 (IP-10; p = 0.012) and tumor necrosis factor (TNF; p = 0.032) in patients with evolving clinical relapse. Sparse partial least-squares multivariate analyses (sPLS-DA) showed higher first component values for the clinical relapse group compared to the other groups, separation was driven mainly by IP-10, TNF, IL-9, IFN-γ, MIP-1β, and IL-12. Our results demonstrate that evolving clinical relapse after NA cessation is associated with a systemic increase in the proinflammatory cytokines IP-10 and TNF. | |
dc.language | EN | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Treatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines | |
dc.title.alternative | ENEngelskEnglishTreatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines | |
dc.type | Journal article | |
dc.creator.author | Holmberg, Marte | |
dc.creator.author | Aass, Hans Christian | |
dc.creator.author | Dalgard, Olav | |
dc.creator.author | Samuelsen, Ellen | |
dc.creator.author | Sun, Dan | |
dc.creator.author | Björkström, Niklas K. | |
dc.creator.author | Johannessen, Asgeir | |
dc.creator.author | Reikvam, Dag Henrik | |
cristin.unitcode | 185,53,0,0 | |
cristin.unitname | Institutt for klinisk medisin | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 2218683 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Scientific Reports&rft.volume=13&rft.spage=&rft.date=2023 | |
dc.identifier.jtitle | Scientific Reports | |
dc.identifier.volume | 13 | |
dc.identifier.issue | 1 | |
dc.identifier.doi | https://doi.org/10.1038/s41598-023-50216-y | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 2045-2322 | |
dc.type.version | PublishedVersion | |
cristin.articleid | 22590 | |